![]() |
产地 | 中国 |
品牌 | Chemstan |
保存条件 | |
货号 | CS016016 |
用途 | 科研用途 |
应用范围 | Research Grade Biosimilar |
抗原来源 | |
保质期 | |
抗体名 | Research Grade Lusvertikimab |
是否单克隆 | |
克隆性 | |
靶点 | |
适应物种 | Human |
形态 | Liquid |
宿主 | Humanized |
标记物 | |
包装规格 | 100ug |
亚型 | IgG4-Kappa |
标识物 | |
浓度 | 95% |
免疫原 | |
是否进口 | 否 |
Catalog No.
CS016016
Species reactivity
Human
Applications
Research Grade Biosimilar
Host species
Humanized
Isotype
IgG4-Kappa
Expression system
Mammalian Cells
Clonality
Monoclonal
Target
IL7R, Interleukin-7 receptor subunit alpha, IL-7R-alpha, IL-7 receptor subunit alpha, CD127, CDw127, IL-7R subunit alpha, IL-7RA
Concentration 1mg/mlEndotoxin level
Please contact the lab for this information.
Purity
>95% purity as determined by SDS-PAGE.
Purification
Protein A/G, purified from cell culture supernatant.
Accession
P16871
Form
Liquid
Storage buffer
0.01M PBS,pH7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -698°C.
Alternate Names
Effi-7,Effi7-h,MD-707,CAS:2375835-91-7
Background
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research.
Note
For research use only. Not for use in clinical or therapeutic applications.